Eligibility criteria: Adults (≥18) with specific advanced cancers (melanoma/gynecologic) meeting measurable disease requirements, adequate organ function, and prior therapy specifications. Key exclusions: active brain metastases, uncontrolled comorbidities, recent anticancer therapy, pregnancy/nursing, other active malignancies, or significant cardiac/CNS history. Cohort-specific requirements apply for platinum resistance and prior treatments.

In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.

In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.

In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.

In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.

In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.

In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.

In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.

In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.

In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.

In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.

In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.

In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.